Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.

IF 2.6 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2025-04-01 Epub Date: 2025-03-17 DOI:10.1080/14796694.2025.2476930

Jingdong Zhang, Guangyu Wang, Xianhe Xie, Wensheng Pan, Qian Dong, Nianhai Zhang, Jie Dong, Li Zhou, Chan Zhou, Jinnan Li, Grace Segall, Yanqiao Zhang

{"title":"Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.","authors":"Jingdong Zhang, Guangyu Wang, Xianhe Xie, Wensheng Pan, Qian Dong, Nianhai Zhang, Jie Dong, Li Zhou, Chan Zhou, Jinnan Li, Grace Segall, Yanqiao Zhang","doi":"10.1080/14796694.2025.2476930","DOIUrl":null,"url":null,"abstract":"Aims: Describe the characteristics, treatment patterns and outcomes of Chinese patients with unresectable advanced/metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA).Methods: This multicenter, retrospective, observational study included adults diagnosed with UAM GA/GEJA in China from 2017-2020.Results: Among 2,745 patients, 1,902, 729, and 284 received first-, second- and third-line (1 L, 2 L and 3 L) therapy-respectively. Most patients received chemotherapy alone in 1 L (84.1%) and 2 L (63.6%), and targeted-therapy-based treatment in 3 L (49.2%). Median real-world progression-free survival (rwPFS) was 6.5, 4.2, and 3.2 months in 1 L, 2 L, and 3 L, respectively.Conclusions: Chinese patients with UAM GA/GEJA mainly received chemotherapy alone in 1 L/2 L and targeted therapy in 3 L. Median rwPFS was short in all lines, highlighting the need for more effective treatments.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1179-1188"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988209/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2476930","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Describe the characteristics, treatment patterns and outcomes of Chinese patients with unresectable advanced/metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA).

Methods: This multicenter, retrospective, observational study included adults diagnosed with UAM GA/GEJA in China from 2017-2020.

Results: Among 2,745 patients, 1,902, 729, and 284 received first-, second- and third-line (1 L, 2 L and 3 L) therapy-respectively. Most patients received chemotherapy alone in 1 L (84.1%) and 2 L (63.6%), and targeted-therapy-based treatment in 3 L (49.2%). Median real-world progression-free survival (rwPFS) was 6.5, 4.2, and 3.2 months in 1 L, 2 L, and 3 L, respectively.

Conclusions: Chinese patients with UAM GA/GEJA mainly received chemotherapy alone in 1 L/2 L and targeted therapy in 3 L. Median rwPFS was short in all lines, highlighting the need for more effective treatments.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国晚期或转移性胃/胃食管交界腺癌的治疗模式和结果。

目的：描述中国晚期/转移性（UAM）胃/胃食管交界处腺癌（GA/GEJA）患者的特征、治疗模式和预后。方法：这项多中心、回顾性、观察性研究纳入了2017-2020年中国诊断为UAM GA/GEJA的成年人。结果：在2745例患者中，19027例、729例和284例分别接受了一线、二线和三线（1l、2l和3l）治疗。大多数患者在1 L（84.1%）和2 L（63.6%）接受单独化疗，在3 L（49.2%）接受靶向治疗。1l、2l和3l患者的中位无进展生存期（rwPFS）分别为6.5、4.2和3.2个月。结论：中国UAM GA/GEJA患者以1 L/2 L单方化疗为主，3 L靶向治疗为主。所有研究的中位rwPFS都很短，这表明需要更有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.